CLN-978

· Cullinan Therapeutics Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for CLN-978, covering 2024-05-02 to 2026-03-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease [Phase 1]

See pricing